Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Insys to pay $225 million, plead guilty in U.S. over opioid kickbacks

Insys Therapeutics Inc. agreed to pay $225 million and an operating unit will plead guilty to fraud to settle probes into their payment of kickbacks to induce doctors to prescribe highly addictive opioids, the U.S. Department of Justice said.

Read More »

U.S. charges pummel drugmaker Indivior, hurt Reckitt

Indivior Plc lost three-quarters of the company’s stock market value and former parent Reckitt Benckiser also fell after the U.S. Justice Department accused the British drugmaker of illegally boosting prescriptions for the blockbuster opioid addiction treatment Suboxone.

Read More »

Major study debunks healthy moderate drinking myth

Blood pressure and stroke risk rise steadily the more alcohol people drink, and previous claims that one or two drinks a day might protect against stroke are not true, according to a genetic study.

Read More »

Advocacy Group and FDA Advisor Call for a Moratorium on Opioid Approvals

As America continues to grapple with the opioid crisis, nonprofit advocacy group Public Citizen is calling for the U.S. Food and Drug Administration (FDA) to place a moratorium on the approval of any new opioid medications.

Read More »

Indivior launches generic version of own opioid drug

Indivior launched a copycat version of the opioid addiction drug Suboxone in the U.S., one day after a court decision cleared the way for rivals to market generic forms of the blockbuster medicine.

Read More »

U.S. top court rejects bid to block Indivior opioid drug copycat

The U.S. Supreme Court dealt a blow to Indivior Plc on Tuesday, clearing the way for a copycat version of the British pharmaceutical firm’s lucrative opioid addiction treatment Suboxone Film in a victory for India-based generic drug maker Dr. Reddy’s Laboratories Ltd.

Read More »

Indivior loses U.S. district court battle, copycat launches imminent

Generic competitors to British drugmaker Indivior Plc’s blockbuster opioid addiction treatment are on course to launch after the firm’s attempt to stay a U.S. District court judgement was rejected.

Read More »

Indivior temporarily stops rival Alvogen’s generic launch

Indivior said a U.S. district court had granted the British drugmaker a temporary restraining order, stopping rival Alvogen from launching cut-price versions of the company’s blockbuster opioid addiction treatment.

Read More »

U.S. substance abuse helpline largely unknown

The U.S. government’s toll-free substance abuse helpline, which provides free referral services to those looking for treatment, gets little publicity, a new study finds.

Read More »

Connecticut Judge Dismisses Opioid Drug Lawsuits

A judge dismissed lawsuits filed by 37 different municipal governments pertaining to opioid drugmakers being sued in the state of Connecticut.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom